.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for introduction of people with MASLD and also dimension of liver outcomes in cardio-- kidney-- metabolic tests, when data propose mechanistically plausible advantages and scientific safety and security-- as well as lays out points to consider for trial design as well as regulatory approval.